Brazil’s new process for examining pharma patents faces scepticism

A new procedure for approving pharmaceutical patents in Brazil comes into effect on June 12 with the aim of ending the arduous double examination by the BPTO and Anvisa. Uncertainties such as whether the national health agency will be happy to be overruled by BPTO will need to be resolved to overcome doubts, however
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: